IFLScience on MSN
Alzheimer’s drugs that target amyloid plaques have no meaningful effects, says major review, sparking fierce debate from scientists
Alzheimer’s disease drugs that target amyloid-β, one of the problematic proteins associated with the disease, may have “no ...
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have ...
Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.
Add Yahoo as a preferred source to see more of our stories on Google. An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to ...
Top drugmakers have spent more than a decade investigating and advancing anti-amyloid Alzheimer's medicines in clinical ...
A new study challenges the long-standing view that Alzheimer’s is driven primarily by amyloid plaques, instead pointing to a ...
Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major ...
A major global review finds new Alzheimer’s drugs offer little meaningful benefit despite clearing brain plaques, raising ...
Anti-amyloid drugs have been considered game-changing for Alzheimer's, but an extensive review has revealed that the drugs ...
The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein ...
Researchers at Niigata University have used advanced three-dimensional (3D) imaging to reveal how amyloid β (Aβ) deposits spread along blood vessels in the human brain in cerebral amyloid angiopathy ...
Findings showed 91.7% of patients with positive results using Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test had amyloid plaques based on PET scan or CSF test results. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results